Evaluation of the Impact of Orange Juice on Apixaban Pharmacokinetics in Healthy Rats
DOI:
https://doi.org/10.35516/jjps.v17i1.1795Keywords:
AP (AP), HPLC, method validation, orange juice (OJ), Citrus sinensis pharmacokinetic interactionsAbstract
Juice derived from the "sweet orange" cultivar is widely consumed and is considered one of the most popular juices globally. It contains many bioactive compounds that can interact with pharmaceutical agents. This study aimed to assess the impact of oral co-ingestion of orange juice (OJ) and Apixaban (AP) on the fundamental pharmacokinetic characteristics of AP, Cmax, and AUC0-t. Two groups of Wistar rats were used in this study: one was given the drug alone, and the other was given the drug with OJ. Each animal was given 10 ml of freshly squeezed orange juice two hours before the administration of AP at a dose of 5 mg/kg and 10 ml concurrently with it. The plasma samples were withdrawn up to 72 hours later and analyzed using the LC/MS technique, and pharmacokinetic parameters were analyzed using Winnonlin version 8.3. The findings indicated a statistically significant increase in Cmax of AP from 28.12±3.78 ng/mL to 56.97±9.8 ng/mL, as well as an increase in AUC0-12 levels from 285.04±24.5 ng. hr/mL to 827.17±46.58 ng.hr/mL when ingested with OJ, without a significant change in Tmax and half-life (t1/2). The results determined that consuming sweet OJ exhibits a noteworthy interaction with orally administered AP.
References
Matzke G R., Aronoff G R., Atkinson A J., Bennett W M., Decker B S., Eckardt K. U., Golper T., Grabe D W., Kasiske B., Keller F., Kielstein J T., Mehta R., Mueller B A., Pasko D A., Schaefer F., Sica D A., Inker L A., Umans J G., and Murray P. Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease. Improving Global Outcomes (KDIGO). Kidney. Int. 2011; 80(11):1122–1137. DOI: https://doi.org/10.1038/ki.2011.322
Palleria C., Di Paolo A., Giofrè C., Caglioti C., Leuzzi G., Siniscalchi A., De Sarro G., and Gallelli, L. Pharmacokinetic drug-drug interaction and their implication in clinical management. J. Res. Med. Sci. 2013; 18(7):600–609.
Almomani E Y., Jarrar W., Alhadid A., Hamadneh L., Qablan A., and Almomani, H. Y. Shedding light on pharmacists’ knowledge of kidney stones’ etiology and treatment. J. Pharm. Pract. 2022; 20(3). DOI: https://doi.org/10.18549/PharmPract.2022.3.2712
Koziolek M., Alcaro S., Augustijns P., Basit A W., Grimm M., Hens B., Hoad C. L., Jedamzik P., Madla C M., Maliepaard M., Marciani L., Maruca A., Parrott N., Pávek P., Porter C J H., Reppas C., van Riet-Nales D., Rubbens J., Statelova M., … Corsetti M. The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. Eur. J. Pharm. Sci. 2019; 134:31–59. DOI: https://doi.org/10.1016/j.ejps.2019.04.003
Abu Dayyih W., Mallah EM., Al-Ani I., Arafat T. Liquorice Beverage Effect on The Pharmacokinetic Parameters Of Atorvastatin, Simvastatin, And Lovastatin By Liquid Chromatography-Mass Spectroscopy/Mass Spectroscopy. Asian J. Pharm. Clin. Res. 2016; 9(2):143-179.
Miller N H. Compliance with treatment regimens in chronic asymptomatic diseases. Am. J. Med. 1997; 102(2A):43–49. DOI: https://doi.org/10.1016/S0002-9343(97)00467-1
Paudel S., Palaian S., Shankar P R., and Subedi N. Risk Perception and Hesitancy Toward COVID-19 Vaccination Among Healthcare Workers and Staff at a Medical College in Nepal. Risk. Manag. Health Policy. 2021; 14: 2253–2261. DOI: https://doi.org/10.2147/RMHP.S310289
Cheng L., and Wong H. Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool. Int. J. Pharm. 2020; 12(7):1–18. DOI: https://doi.org/10.3390/pharmaceutics12070672
Bushra R., Aslam N., and Khan A Y. AP: A Clinical Pharmacokinetic and Pharmacodynamic Review, 58. Clinical. Pharmacokinetics. 2019. Food-drug interactions. Oman. Med. J. 2011; 26(2):77–83. DOI: https://doi.org/10.5001/omj.2011.21
Genser D., Food and drug interaction: consequences for the nutrition/health status. Ann. Nutr. Metab. 2008; 52 (1): 29–32. DOI: https://doi.org/10.1159/000115345
Rodriguez-Fragoso, Lourdes, and Jorge Reyes-Esparz. ‘Fruit/Vegetable-Drug Interactions: Effects on Drug Metabolizing Enzymes and Drug Transporters’. Drug. Discov. InTech, 2013. DOI: https://doi.org/10.5772/48283
Alam M.A., Subhan N., Rahman M.M., Uddin S.J., Reza H M., Sarker, S. D. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv. Nutr. 2014; 5(4):404–417. DOI: https://doi.org/10.3945/an.113.005603
Vanapalli, S. R., Chen, Y., Ellingrod, V. L., Kitzman, D., Lee, Y., Hohl, R. J., & Fleckenstein, L. Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers. Clin. Pharmacol. Ther. 2003; 73(2): 94–94. DOI: https://doi.org/10.1016/S0009-9236(03)90702-8
Lilja J.J., Raaska K., Neuvonen, P.J. Effects of OJ on the pharmacokinetics of atenolol. European Journal of Clin. Pharmacol. 2005; 61:337–340. DOI: https://doi.org/10.1007/s00228-005-0930-9
Neuhofel A.L., Wilton J.H., Victory J.M., Hejmanowski L.G., Amsden G.W. Lack of bioequivalence of ciprofloxacin when administered with calcium‐fortified orange juice: a new twist on an old interaction. J. Clin. Pharmacol. 2002; 42(4):461–466. DOI: https://doi.org/10.1177/0091270002424013
Kamath A.V., Yao M., Zhang Y., Chong S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. Jordan j. pharm. Sci. 2005; 94(2):233–239. DOI: https://doi.org/10.1002/jps.20231
Williamson E M. Drug interactions between herbal and prescription medicines. Drug. Saf. 2003; 26(15):1075–1092. DOI: https://doi.org/10.2165/00002018-200326150-00002
AbuDayyih WA, Manaysa MH, Hailat M., Zakareia Z., El Hajji F. Influence of Castor Oil on Glycated Hemoglobin (HbA1c) on Induced Type 2 Diabetes Mellitus in Rats. Jordan j. pharm. Sci. 2021; 14(3):341-349.
Sa`adeh A., Aburjai T., Shraim N., Al-Ghazawi M. The Effect of Brassica Oleracea (Cabbage) on The Pharmacokinetics of Ciprofloxacin in an Animal Model. Jordan j. pharm. sci. 2019; 12(2): 59–67.
Frost C, Shenker A, Jhee S, et al. Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. Clin Pharmacol. 2018; 10:153-163. DOI: https://doi.org/10.2147/CPAA.S169505
Habash I W., Al-Shdefat R I., Hailat M M., Dayyih W A., and Abu Dayyih W A. stability indicating RP-HPLC method development for simultaneous estimation of alogliptin, pioglitazone, and metformin in pharmaceutical formulations. Acta. Pol. Pharm. 2020; 77(4):549–562. DOI: https://doi.org/10.32383/appdr/125774
Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol. 2008; 4(7):923-939. DOI: https://doi.org/10.1517/17425255.4.7.923
Honda Y, Ushigome F, Koyabu N, et al. Effects of grapefruit juice and OJ components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004; 143(7):856-864.
Wang L., He K., Maxwell B., Grossman S J., Tremaine L M., Humphreys W G., and Zhang D. Tissue distribution and elimination of [14C] AP in rats. Drug. Metab. Dispos. 2011; 39(2): 256–264. DOI: https://doi.org/10.1124/dmd.110.036442
Hellwig T., and Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 2013; 47(11):1478–1487. DOI: https://doi.org/10.1177/1060028013504741
Honda Y., Ushigome F., Koyabu N., Morimoto S., Shoyama Y., Uchiumi T., Kuwano M., Ohtani H., and Sawada Y. Effects of grapefruit juice and OJ components on P-glycoprotein- and MRP2-mediated drug efflux. Br. J. Pharmacol. 2004; 143(7): 856. DOI: https://doi.org/10.1038/sj.bjp.0706008
Byon W, Garonzik S, Boyd RA, Frost CE. AP: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin. Pharmacokinet. 2019; 58(10):1265-1279. DOI: https://doi.org/10.1007/s40262-019-00775-z
